SINUGENIX
DEAD

Serial Number

85072016

Owner

SinuGenix, LLC

Attorney

Sherri L. Rohlf

Filing Date

Jun 25, 2010

Add to watchlist:

No watchlists yet
View on USPTO

SINUGENIX Trademark

Serial Number: 85072016

SINUGENIX is a trademark filed by SinuGenix, LLC on June 25, 2010. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 11 (Environmental Control). The application is currently no longer active.

Owner Contact Info

SinuGenix, LLC (2 trademarks)

Suite 260
Minneapolis, MN 55416

Entity Type: 16

Trademark Details

Filing Date

June 25, 2010

Registration Date

Not Registered

Published for Opposition

April 10, 2012

Goods & Services

Allergy medications, Allergy eye drops, Allergy relief medications, namely, allergy prevention spray, allergy protective screens, allergy antigens; Antifungal creams for medical use; Antibiotics, antibiotic creams and ointments, antibiotic ophthalmological ointments and solutions, anti-inflammatory decongestants, antihistamine eye drops, moisturizing eye drops, antihistamine nasal sprays, antihistamines; Aromatherapy oils, other than essential oils for treating nasal congestion, fatigue and decreased immunity; Preparations for treatment of asthma; Medical cleansers for skin and wounds; Medical creams for skin care; Decongestants; Cough treatment preparations; Cough suppressants; Injectable epinephrine (EPI) pens and racemic epinephrine for inhalation therapy (nebulization); Nutritionally fortified water, namely, electrically charged water; Medicated hair care preparations; Herbs for medicinal purposes; Natural herbal supplements used in ayurvedic medicines; Homeopathic supplements; Diagnostic test patch for application to the skin for determining allergies; leukotriene inhibitors, namely, pharmaceutical preparations that blunt the inflammatory allergic and asthma inducing response; Moisturizing nasal sprays, moisturizing saline gels solutions for medical purposes; Antimicrobial coatings to treat the growth of mold, mildew, bacteria and fungus on various surfaces; Pharmaceutical preparations that reduce the viscosity of respiratory mucus; Nasal anticholinergic sprays, nasal decongestants, nasal rinse, nasal steroid spray; Nutraceuticals for use as a dietary supplement; Medications that reduce the release of acid to treat reflux and ulcers; H-2 histamine blockers, namely, medication that reduces the release of histamine; Pharmaceutical preparations for the treatment of dermatitis, urticaria, psoriasis, angioedema, bacterial, viral, fugal and yeast skin infections; Anti-viral medications for skin cleansers; Pain relief medications; cleaning for medical use, namely, sterile solutions for nebulizers; Inhalers filled with racemic epinephrine, long and short acting beta agonsists, inhaled corticosteroids and salmeterol; Customized anti-biotic preparations for use with nebulizers; Vitamins; mineral, dietary and nutritional supplements; Antibacterial, antiviral and anti-inflammatory pharmaceuticals engineered with silver particles and NANO technology; Pharmaceutical preparations in the form of gels and rinses for use as custom nasal prescription formulations and novel bacterial applications consisting of blends of antibiotics, anti-fungal agents and steroid combinations

Air filtration installations; Air filtering installations, namely, gas phase and hybrid filters; HEPA filters for household use; HEPA vacuum cleaners for household purposes; Humidifiers; UV lamps

Respiratory masks for medical purposes; Medical apparatus and units for dosage, measuring and monitoring, namely, drug delivery devices and systems for custom nasal prescription formulations and novel bacterial applications consisting of blends of antibiotics, anti-fungal agents and steroid combinations which are available in various topical delivery systems including gels, rinses and nebulization devices of various sizes; Medical apparatus and units for dosage measuring and monitoring, namely, drug delivery devices and systems for use in measuring charged particles (activated water), nitric oxide gas, UV light and laser ionization delivery; External nasal dilators and internal nasal splints "springs" and internal nasal dilators; Nebulizers for respiration therapy; nasal irrigation vessel and mechanical installation device; Inhalers for medical purpose; Replacement parts for nebulizers, namely, mouthpieces, masks, chinstraps, filters and tubing; Spirometer/peak flow meters, namely, devices used to measure breathing capacity in asthmatics and chronic obstructive pulmonary disease patients; Instruments and apparatus provided empty for the inhalation of pharmaceuticals designed to deliver cleansing via balanced sterile saline solution into the respiratory and medications to improve ventilation by their various anti-inflammatory, anti-bacterial, anti-fungal, mucolytic and cronchi-dilatory effecters

Filing History

ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Jan 7, 2013 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jan 7, 2013 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 5, 2012 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 10, 2012 NPUB
PUBLISHED FOR OPPOSITION
Apr 10, 2012 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 21, 2012 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 5, 2012 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 2, 2012 CNSA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 20, 2012 TCCA
EXAMINER'S AMENDMENT ENTERED
Feb 20, 2012 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 20, 2012 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 20, 2012 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 20, 2012 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 31, 2012 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 31, 2012 CRFA
PETITION GRANTED - RESPONSE RECEIVED
Jan 27, 2012 PGRR
ASSIGNED TO PETITION STAFF
Jan 12, 2012 APET
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 20, 2011 TROA
TEAS PETITION TO REVIVE RECEIVED
Dec 20, 2011 PROA
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Dec 16, 2011 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Dec 15, 2011 ABN2
NOTIFICATION OF FINAL REFUSAL EMAILED
May 17, 2011 GNFN
FINAL REFUSAL E-MAILED
May 17, 2011 GNFR
FINAL REFUSAL WRITTEN
May 17, 2011 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 22, 2011 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 22, 2011 CRFA
ASSIGNED TO LIE
Apr 15, 2011 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 13, 2011 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 14, 2010 GNRN
NON-FINAL ACTION E-MAILED
Oct 14, 2010 GNRT
NON-FINAL ACTION WRITTEN
Oct 14, 2010 CNRT
ASSIGNED TO EXAMINER
Sep 30, 2010 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 30, 2010 NWOS
NEW APPLICATION ENTERED
Jun 29, 2010 NWAP